Spexis AG (SIX:SPEX) is a publicly-listed Swiss clinical-stage biopharmaceutical company developing rare disease and oncology treatments in indications where new therapeutic options are urgently needed. Spexis AG was launched in December 2021 by the reverse merger of EnBiotix, Inc. (Boston, MA, USA) and Polyphor AG (Allschwil, Switzerland), with EnBiotix shareholders resulting in the majority. Our focus is on chronic respiratory diseases (CRD), and our lead product candidate ColiFin® is P3 ready. ColiFin® is an inhaled colistimethate sodium product in-licensed from PARI Pharma GmbH for ex-European rights. Approved and marketed in Europe as a front-line therapy in cystic fibrosis (“CF”) patients, ColiFin® already has a proven safety, efficacy, and commercial track record. In the U.S., ColiFin® has Orphan Drug and Qualified Infectious Disease Product (“QIDP”) designations, which together will provide a total of 12 years of market exclusivity from NDA approval. We also have a “Study May Proceed” letter from the FDA regarding a single phase 3 study evaluating ColiFin® in CF patients being sufficient to support a future New Drug Application (“NDA”). The trial design has been endorsed by the Cystic Fibrosis Foundation (CFF) Therapeutic Development Network (TDN), the clinical development arm of the CFF. Of note, the CFF also invested in the pre-merger financing launching Spexis.
Location: Switzerland, Basel-Country, Allschwil
Employees: 11-50
Total raised: $2.5M
Founded date: 1996
Investors 2
Date | Name | Website |
- | SPRIM Glob... | sprim.net |
27.01.2022 | CARB-X | carb-x.org |
Funding Rounds 1
Date | Series | Amount | Investors |
15.08.2023 | - | $2.5M | - |
Mentions in press and media 16
Date | Title | Description | Source |
15.01.2024 | Basilea acquires Spexis preclinical antibiotics program | Infections by multidrug-resistant Gram-negative bacteria (GNB) are a major challenge for healthcar... | startuptic... |
15.08.2023 | Spexis Raises USD$2.5M in Funding | Spexis AG (SIX: SPEX), an Allschwil, Switzerland-based clinical-stage biopharmaceutical company, ann... | finsmes.co... |
15.08.2023 | Spexis and Addex attract new funds | Spexis AG, a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare ... | startuptic... |
15.08.2023 | Spexis announces USD $2.5 million capital commitment to supp... | Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) -... | einpresswi... |
14.08.2023 | Spexis announces USD $2.5 million capital commitment to supp... | ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) — Spexis AG (SIX: SPEX), a clinical-stage bio... | sprim.net/... |
18.04.2023 | Spexis announces closing of capital commitment of USD 4.5 mi... | Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, April 18, 2023 (GLOBE NEWSWIRE) ... | sprim.net/... |
16.01.2023 | Listed Swiss Biotechs at full throttle | Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new... | startuptic... |
22.09.2022 | Spexis announces positive renal impairment clinical trial re... | Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and w... | globenewsw... |
06.09.2022 | Spexis provides business update and announces financial resu... | Ad hoc announcement pursuant to Art. 53 LR Study start-up activities nearly complete for COPILOT, th... | globenewsw... |
31.08.2022 | Spexis announces presentation of half-year 2022 financial re... | ALLSCHWIL, Switzerland, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage bi... | globenewsw... |
Show more